CG Oncology | IPO Presentation Deck | 45 slides

Slide schematic 6/6

diagram 1/1 list 3/3 source-note 1/1 title 1/1

Components 6

process bullet bullet bullet source-note headline

Tools 1

list/bullet: Population: Pathologically confirmed high-risk NMIBC BCG-unresponsive CIS with or without Ta/T1; Have all Ta/T1 disease resected prior to treatment; Trial designed and compliant with 2018 FDA guidance

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 1

process 80%

The slide uses a three-stage horizontal flow to describe the clinical trial structure.

Find anything

The slide uses a process-flow style layout to define the clinical trial parameters.